Ketamine Treatment

HOPE Therapeutics Secures $30M For Ketamine Clinic Expansion, Projects $100M Revenue By 2025
Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Super Model Chrissy Teigen Talks About Ketamine Therapy Session, Says She Saw 'Space & Time'
Defense Dept. Funds Ketamine Study For PTSD Treatment In 600 Service Members & Veterans

Ketamine Treatment Recent News

PharmaTher Is 'One Step Closer To Being A Ketamine Leader' Due To FDA Acceptance
The Food and Durg Administration (FDA) has accepted specialty biopharma company PharmaTher Holdings’ (OTCQB: PHRRF) new drug application for a racemic ketamine product. 
PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application
Specialty biotech company PharmaTher Holdings (OTCQB: PHRRF) reported it has submitted a priority-original Abbreviated New Drug Application (ANDA) for its proprietary racemic ketamine, KETARX, t
Breaking Ground In Prevention & Relief Of Anxiety & PTSD: Silo Pharma' Nasal Formulation For Ketamine-Based Treatment
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharma company merging traditional therapeutics with psychedelic research, has advanced the formulation development for its ketamine-composed drug SPC-15. 
Awakn Life Sciences Becomes Pure R&D Biotech After Sale Of Norway Clinics
As part of its business restructuring process and following its London clinics busin
Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets
Specialty biotech company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has filed a pre-submission facility correspondence in advance of its Abbreviated New Drug Application (ANDA) for its novel racemic ketamine KETARX to the FDA.
Silo Pharma's New Ketamine Implant For Fibromyalgia And Chronic Pain Is In The Making
Developmental-stage psychedelics biotech Silo Pharma (NASDAQ: SILO) has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant with fibromyalgia and chronic pain as the initially targeted indications. 
Seelos Therapeutics Positive Q1 Financials Make For 'The Most Important Year' In Company's History
Clinical-stage biopharma company Seelos Therapeutics Inc. (NASDAQ: SEEL) reported financial results and clinical updates corresponding to the first quarter ended March 31, 2023. Quarterly numbers show:
Stress-Related Mood Disorders And Alzheimer's: Can This Patented Ketamine Drug Help?
Silo Pharma Inc. (NASDAQ: SILO), one of the biotech companies developing next-generation psychedelic therapeutics, obtained a new US patent covering IP for its drug candidate SPC-15’s research and development.
Atai Advances R-Ketamine Through Phase 1 Bridging Study, Update And Near-Term Expectations
Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) announced the dosing of the first subject in majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous
Ketamine Company Advances Parkinson's Treatment Through Final Stages Toward FDA Approval
PharmaTher Holdings Ltd.
Silo Pharma To Patent Novel Ketamine-Based Treatment For Chronic Condition
Biopharma company Silo Pharma Inc.
PTSD Treatment Is On The Horizon: A New Cream Could Be The Answer
Biotech company Psycheceutical Bioscience Inc.
Major Ketamine Clinics Chain Decides Not To Pursue Acquisition Deal
Irwin Naturals Inc.
Awakn's First Licensing Partnership Deal In Europe Involves Chain Of Portuguese Clinics
Awakn Life Sciences Corp. (OTCQB: AWKNF) has signed a licensing partnership agreement in Europe with a Portugal-based healthcare consortium currently operating in stealth mode.  
Novel Ketamine Topical Cream To Treat PTSD Gets First In-Human Trials
Psycheceutical Bioscience (OTCPK: BWVI) is advancing its proprietary ketamine topical formulation into clinical studies. The life sciences company has partnered with Australian-based contract research organization iNGENū Pty Ltd. 
Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program
Awakn Opens Fourth European Clinic, Norway Takes Center Stage
Seelos Dosing Participants In Psychedelics Study, Seeks Japanese Subjects In Major Depression Therapy
Clinical-stage biopharma psychedelics company Seelos Therapeutics Inc.
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items.
Israeli Biotech Develops Ketamine Analogue To Treat Major Depression With Promising Results
Israeli-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) and partners Bar-Ilan University and Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center have obtained positive results from the latest preclinical trial on a next-gen psychedelic for the treatment of Major
FDA Green Lights New Study Testing IV Ketamine Infusion For Depressive Disorder
After a full review of healthcare provider Ehave Inc.'s (OTC Pink: EHVVF) IND application, the U.S.
FDA OKs Ketamine For Treating Organ Transplant Injuries With 'Orphan Drug' Status
The U.S. Food and Drug Administration (FDA) has granted PharmaTher Holdings Ltd. (OTCQB: PHRRF) an Orphan Drug designation for ketamine in the prevention of injury from organ transplantation.
Psychedelic-Assisted Therapies: Upcoming Moves In Montana, Colorado And Ontario
While psychedelics are still listed as Schedule I substances making them illegal under federal law, companies across North America are preparing to address patients’ needs in the hopefu
This New Psychedelic Therapy Program Will Accompany Patients In Their Healing Journey For A Whole Year
Psychedelics-assisted therapy provider Field Trip Health & Wellness Ltd. has launched Freedom by Field Trip, a novel and unmatched one-year hybrid program combining ketamine-assisted therapy (KAP) with holistic wellness support.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved